NovMetaPharma Co., Ltd.

A229500

KR7229500004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2023-07-26 EDT			5-day change	1st Jan Change
20,500 ^KRW	+2.24%		-.--%	-.--%

2023	NovMetaPharma Co., Ltd. agreed to acquire SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction	CI
2023	NovMetaPharma Co., Ltd. announced that it has received KRW 6.99999258 billion in funding from BNC Korea Co., Ltd.	CI

NovMetaPharma Co., Ltd. announced that it has received KRW 1.86 billion in funding

August 24, 2017

On August 25, 2017, NovMetaPharma Co., Ltd. (XKON:A229500) closed the transaction.

Latest news about NovMetaPharma Co., Ltd.

NovMetaPharma Co., Ltd. agreed to acquire SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction	23-07-26	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 6.99999258 billion in funding from BNC Korea Co., Ltd.	23-06-28	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 6.99999258 billion in funding from BNC Korea Co., Ltd.	23-06-20	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 3.299969948 billion in funding from Road Jeilho Bio Private Equity Joint Venture Company	23-03-28	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 3.299969948 billion in funding from Road Jeilho Bio Private Equity Joint Venture Company and other investors	23-03-06	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 3.8000182 billion in funding from Heungkuk Life Insurance Co., Ltd.	21-11-18	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 3.8000182 billion in funding from Heungkuk Life Insurance Co., Ltd.	21-11-10	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 3 billion in funding	21-08-19	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 3 billion in funding	21-08-17	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 4.511234288 billion in funding from Intellectual Discovery Co., Ltd.	19-04-18	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 4.511234288 billion in funding from Intellectual Discovery Co., Ltd.	19-04-07	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 10.22 billion in funding from KMH Co. Ltd., Whale Investment and other investors	17-12-05	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 10.22 billion in funding from KMH Co. Ltd., Whale Investment and other investors	17-12-04	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 1.86 billion in funding	17-08-24	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 1.86 billion in funding	17-08-23	CI

NovMetaPharma Co., Ltd. is a Korea-based company mainly engaged in the development and sale of pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment is involved in the development and sale of diabetes treatment, obesity treatment, osteoporosis treatment, alzheimer's disease treatment, and autoimmune enhancers. The Health Functional Food segment is engaged in the manufacturing and sale of health functional food related to blood sugar, prostate health, comprehensive minerals, and cognitive improvement. It also produces and sells vinegar drinks. The Company distributes its products within the domestic market and to overseas markets, including America and China.

Sector

Biotechnology & Medical Research

Calendar

2024-05-24 - Investor Meeting

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NOVMETAPHARMA CO., LTD.	-.--%	136M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
BIONTECH SE	-14.15%	21.84B
ARGENX SE	-1.05%	21.96B
GENMAB A/S	-5.29%	19.21B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
BEIGENE, LTD.	-4.16%	18.08B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs